Pages
- About us
- Accueil
- All events
- Commercial Manufacturing
- Confidentiality Policy
- Contact & Quotation Request
- Contact the Personal Data Protection Officer
- Cosmetic Peptides
- COVID-19 Information
- Custom R&D
- Generic peptides
- Individualized Peptides
- News
- Personal data
- Quality at PolyPeptide
- Request our Documentation
- Scale and Synthesis strategy
- Services
Posts by category
- Category: Non classé
- PolyPeptide News Flash, #2, 2020
- Information Letter on COVID-19
- Information Letter on COVID-19
- New member of the Medicon Valley Alliance
- PolyPeptide News Flash February 2020
- Innovation and Technology
- PolyPeptide News Flash October
- Press release: the start of a research collaboration program with IBMM in Montpellier, France
- Symposium on Preparative and Process Scale HPLC, MCC and SFC 2019
- Book your meeting with PolyPeptide at CPhI worldwide – Frankfurt, Germany 5-7 November 2019
- 100% Sustainable energy from wind turbines at PolyPeptide Sweden
- PolyPeptide attends TIDES Europe – Amsterdam, November 7th and 8th
- Looking forward to seeing you at CPhI Madrid, 9-11 October, Hall 8, stand #8B2
Generic peptides
- Semaglutide
- Triptorelin
- Somatostatin
- PTH (1-34) Teriparatide
- Octreotide
- Liraglutide
- Leuprolide
- Gonadorelin Acetate / HCI
- Felypressin
- Desmopressin
- Deslorelin
- Calcitonin
- Atosiban
- Vasopressin, 8-L-Arginine
- Exenatide
- Carbetocin
- ACTH (1-39) Porcine
Events
- TIDES Europe
- TIDES
- TIDES digital week
- CPhI Worldwide
- BIO International Convention San Diego
- MixiiiBIOMED
- CPhI North America - postponed to Sep. 09-11
- 7th Annual Peptides & Oligonucleotides Congress
- Biotech Connection Los Angeles
- Job Days Essenscia, Chime, Pharma & Biotech
- GFPP - Symposium “Cell-Penetrating Peptides: Next Generation Delivery Systems” - Postponed
- Neoantigen Summit
- in-cosmetics global, 6-8 octobre, Barcelona, Spain
- AACR Annual Meeting 2020 postponed to October 05-07
- Canceled: DCAT week
- BIO-EUROPE SPRING
- Asia Tides
- Biofit
Événements
- MORE THAN 30 APPROVED ACTIVE PHARMACEUTICAL INGREDIENTS
- POLYPEPTIDE GROUP ACQUIRED THE NEW BUSINESS AND OPERATIONS OF LONZA IN BRAINE-L’ALLEUD, BELGIUM
- 22 COMMERCIAL PRODUCTS MANUFACTURED AT POLYPEPTIDE
- ACQUISITION OF A NEW BUILDING IN TORRANCE, USA EXPANSION IN MALMÖ, SWEDEN INAUGURATION OF THE FACILITY IN INDIA
- OPENING OF NEW MANUFACTURING PLANT IN STRASBOURG, FRANCE
- ACQUISITION OF THE NEOMPS GROUP
- START OF CONSTRUCTION OF INDIAN FACILITY NEAR MUMBAI
- ACQUISITION OF WHERL GMBH AND PRAGUE POLYPEPTIDE LABORATORIES SRO.
- OPERATIONS START IN TORRANCE, USA
- FOUNDING OF THE POLYPEPTIDE GROUP IN HILLERØD, DENMARK AND TORRANCE, USA
- START OF COMMERCIAL THERAPEUTIC PEPTIDE MANUFACTURE AT MALMÖ IN SWEDEN